Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.32 -1.07 (-1.15%)
Streaming Delayed Price Updated: 3:11 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,... 
Via Benzinga
Exposures COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing... 
Via Benzinga
Exposures COVID-19 Product Safety
This Cheap Stock Is Paying An Unusually High Yield
Gilead has increased their dividend for seven consecutive years. The three-year dividend growth rate of 9.4% shows the level of growth they’re capable of delivering. 
Via Talk Markets
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
Gilead Sciences came out with quarterly earnings of $2.65 per share. 
Via Talk Markets
GILD: Is This Biotech’s 4.2% Yield Healthy?
Gilead’s free cash flow hit a recent peak of $19.5 billion in 2015 before falling each of the next two years, settling around $7.5 billion in 2018. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Healthcare Stocks Subject to Government Policy
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the... 
Via Benzinga
Topics Stocks
Exposures US Equities
5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals
Goldman Sachs predicts the Democrats' new tax plan could yield positive results for M&A-focused companies. Here are the M&A stocks to watch. 
Via InvestorPlace
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates
Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Recap: Gilead Sciences Q3 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021. 
Via Investor's Business Daily
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Gilead Sciences Earnings Preview
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
It's much too early to count these companies out. 
Via The Motley Fool
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
2 High-Yielding Stocks You Can Buy and Hold for Years
They pay more than double what the average S&P 500 stock yields. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
Signs point to yes, but it's still early in the game. 
Via The Motley Fool
Exposures COVID-19
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster... 
Via Benzinga
Exposures COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
A new study shows it is highly effective in preventing deaths if taken early. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.